Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is a biopharmaceutical company focused on cellular metabolism and rare genetic diseases, with its strongest political signal being $1.5M in annual doctor payments and two congressional purchases by a single member.
BusinessWhat AGIO does
Agios Pharmaceuticals develops and commercializes medicines for rare genetic diseases, particularly in hematology and oncology, with revenue derived from product sales and collaborations. Its pipeline includes treatments for pyruvate kinase deficiency and other metabolic disorders. The company operates in a highly regulated FDA environment with no federal contract revenue.
12 months past · 3 months futureAGIO activity timeline
Lifetime Government AwardsAGIO federal contracts
AGIO doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding AGIO
Politicians Trading AGIOMembers of Congress with recent AGIO positions
Congressional TradesWho in Congress is trading AGIO
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting AGIOLive legislation impacting this stock
Political ProfileWhere AGIO sits in Washington
[object Object]
STRUCTURAL: High regulatory density from 8 pharma bills (impact_ratios 0.0088-0.0114) and $1.5M annual doctor payments (get_political_influence.doctor_payments). EVIDENTIARY: Two congressional purchases by one member (bioguide_id C001123) but no corporate insider buys (get_corporate_insider_signal.total_buys: 0). Net: Moderate regulatory exposure with weak transactional signals.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
High regulatory density from FDA oversight and potential legislative impactsFDA, Congress"Recent bill_impacts array shows 8 pharma bills with impact_ratios up to 0.0114"
Regulatory opportunities
-
Potential for orphan drug designations and expedited reviewsFDA"Sector is pharma with rare disease focus, but no specific carveouts in bill_carveouts array"
Capitol Hill AlliesChampions & critics
Congressional champions
- Unknown Unknown
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for AGIO — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades AGIO
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord